Agios Pharmaceuticals, Inc. (AGIO) FinancialsAGIOAgios Pharmaceuticals, Inc.

Evaluating the bottom line, Agios Pharmaceuticals, Inc. maintains a gross margin of 93.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -247.07%, while the net margin is -225.06%. These profitability ratios, combined with a Return on Equity (ROE) of -34.34%, provide a clear picture of how effectively AGIO converts its operational activities into shareholder value.

In the context of the broader market, AGIO competes directly with industry leaders such as SRPT and ZYME. With a market capitalization of $2.08B, it holds a leading position in the sector. When comparing efficiency, AGIO's gross margin of 93.30% stands against SRPT's 62.59% and ZYME's 100.00%. Such benchmarking helps identify whether Agios Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Agios reported a total revenue of $44.7 million in Q2 2026, with a gross margin of 93.3%, reflecting strong profitability on sales despite net losses.